Characteristics of NAKO participants with an iRMD and persons with OA
| RA | AS | PsA | SLE | SjD | iRMD total | OA | N missing | |
| N | 2286 | 571 | 524 | 156 | 95 | 3257 | 24 030 | – |
| Female, % | 73 | 46 | 59 | 81 | 94 | 67 | 59 | 0 |
| Age in years, mean±SD | 58±9.5 | 55±10 | 57±9.5 | 54±11 | 57±9.7 | 57±9.8 | 58±8.7 | 0 |
| Age at onset, mean±SD | 43±15 | 35±13 | n.a.* | 39±14 | 46±13 | 41±15 | Hip: 44±15 Knee: 42±15 Hands: 50±10 | |
| Education, ISCED-97 level,% (n) | 2408 | |||||||
| Lower | 3.9 (88) | 2.3 (13) | 1.9 (10) | 1.9 (3) | 2.1 (2) | 3.4 (109) | 3.4 (869) | |
| Intermediate | 42 (956) | 39 (222) | 42 (216) | 42 (64) | 38 (36) | 41 (1321) | 42 (10 953) | |
| Higher | 43 (977) | 48 (269) | 47 (244) | 48 (74) | 46 (44) | 45 (1453) | 46 (11 800) | |
| Smoking, % (n) | 1625 | |||||||
| Never | 39 (897) | 33 (189) | 33 (172) | 38 (59) | 51 (48) | 38 (1232) | 40 (9541) | |
| Current | 17 (391) | 21 (122) | 16 (86) | 22 (34) | 13 (12) | 18 (575) | 17 (3987) | |
| Former | 36 (819) | 39 (223) | 45 (233) | 33 (52) | 31 (29) | 37 (1211) | 38 (9110) | |
| Comorbidities, % (n) | ||||||||
| Hypertension | 45 (1037) | 40 (229) | 48 (251) | 42 (65) | 35 (33) | 44 (1444) | 43 (10 334) | 72 |
| Hyperlipidaemia | 41 (930) | 35 (201) | 38 (200) | 29 (45) | 38 (36) | 39 (1261) | 37 (8959) | 260 |
| Osteoporosis | 14 (328) | 9.6 (55) | 11 (58) | 14 (21) | 20 (19) | 13 (417) | 7.5 (1802) | 197 |
| Cancer | 12 (268) | 9.8 (56) | 11 (57) | 12 (19) | 14 (13) | 12 (378) | 12 (2794) | 84 |
| Diabetes | 12 (277) | 8.1 (46) | 11 (59) | 6.4 (10) | 5.3 (5) | 11 (356) | 10 (2396) | 42 |
| Reduced renal function | 5.6 (127) | 6.0 (34) | 4.8 (25) | 17 (26) | 15 (14) | 5.6 (187) | 3.5 (839) | 90 |
| Myocardial infarction | 3.9 (90) | 2.6 (15) | 3.1 (16) | 3.2 (5) | 1.1 (1) | 3.5 (115) | 2.7 (650) | 42 |
| Stroke | 2.7 (61) | 2.6 (15) | 2.3 (12) | 3.8 (6) | 4.2 (4) | 2.7 (88) | 2.7 (655) | 62 |
| OA | 65 (1462) | 48 (272) | 56 (289) | 47 (72) | 57 (54) | 59 (1894) | 100 (24 030) | 0 |
SD, based on NAKO data freeze 100 000; application NAKO-603.
*Age at onset only available for psoriasis, not for PsA.
AS, ankylosing spondylitis; iRMD, inflammatory rheumatic disease; ISCED-97, International Standard Classification of Education 97; OA, osteoarthritis; PsA, psoriatic arthritis; RA, rheumatoid arthritis; SjD, Sjögren’s disease; SLE, systemic lupus erythematosus.